What happened with ACON today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Aclarion helps doctors assess which lumbar discs may be causing chronic low-back pain, initially focusing on patients being considered for surgery. Imaging centers send magnetic resonance spectroscopy data—measurements of chemicals in the discs—to its cloud-based Nociscan software. The software measures biomarkers associated with pain and produces a report for the ordering clinician to use alongside other diagnostic information. Aclarion earns revenue from selling these reports; at RadNet imaging centers, it generates the report after RadNet performs the exam.
Sales remain limited. Most revenue comes from the United Kingdom, where insurers reimburse Nociscan scans; U.S. use is mainly funded by direct patient payments. Healthcare providers pay Aclarion using patient charges, payments for associated procedures or UK insurance reimbursement. Aclarion does not bill insurers directly. It plans to secure broader payer coverage, so expanding report sales depends on both clinician adoption and patients’ ability to obtain coverage or pay themselves.
Nociscan works only with certain Siemens and Philips scanner models and configurations. Aclarion also depends on maintaining its University of California license for technology incorporated into its products.
Aclarion considers its current U.S. products exempt from FDA premarket review or outside FDA medical-device regulation, but a different FDA determination could halt sales until authorization is obtained. Continued access to European and UK markets depends on meeting the newer device-certification requirements as existing transitional permissions expire.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aclarion’s results hinge on securing payer coverage and increasing Nociscan scan volumes, while compatibility with Siemens scanners and collaboration with Siemens remain important operational dependencies.
RadNet’s exams feed Aclarion’s report revenue: at three centers owned or operated by RadNet, RadNet performs magnetic resonance spectroscopy (MRS) exams and Aclarion earns revenue by generating Nociscan reports afterward. Watch the volume of those exams at these three centers—not RadNet’s overall imaging volume—to gauge activity supporting Aclarion’s report sales.
RadNet, Inc. earningsRDNT
RadNet performs MRS exams at three centers tied to Aclarion, which earns revenue on the Nociscan reports it generates afterward; RadNet’s report can show whether activity at those centers is feeding that source of Aclarion sales.
The relevant measure is MRS exam volume at these three centers, not RadNet’s total imaging volume. More exams mean more potential Nociscan reports for Aclarion to generate and sell; fewer exams mean this partner channel is offering fewer report-sales opportunities.
Aclarion, Inc. earningsThis company
Aclarion earns revenue when it sells Nociscan reports, and this report will show whether paid report sales are growing faster than the cost of serving them.
Read report revenue alongside cost of revenue, which includes hosting, support and partner fees. Rising revenue with costs contained would show that paid use of Nociscan reports is expanding and each report is supporting the business better; flat or falling revenue with rising costs would show that commercial use remains limited and report sales are not easing the operating loss.
